AI Science Tracker

Precision Scientific (Beijing) Co. Ltd., Beijing, 100085, China.

1 discovery from 2024

Discoveries

ProT-Diff: A Modularized and Efficient Strategy for De Novo Generation of Antimicrobial Peptide Sequences by Integrating Protein Language and Diffusion Models

Source check: Needs source check. Not independent scientific confirmation.

Finding: ProT-Diff: A Modularized and Efficient Strategy for De Novo Generation of Antimicrobial Peptide Sequences by Integrating Protein Language and Diffusion Models. Generated thousands of antimicrobial peptide sequences de novo; 45 selected after physicochemical screening. 44 of 45 peptides were active against Gram-positive or Gram-negative bacteria; one peptide was effective in a drug-resistant E. coli peritonitis model. Evidence limits: Single in vivo model; pharmacology and resistance emergence not assessed. Reviewed from Europe PMC abstract only.

Technology: ProT-Diff: protein language model plus diffusion model

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

AI contribution
Generated thousands of antimicrobial peptide sequences de novo; 45 selected after physicochemical screening.
Test and result
44 of 45 peptides were active against Gram-positive or Gram-negative bacteria; one peptide was effective in a drug-resistant E. coli peritonitis model.
Limitation / still unknown
Single in vivo model; pharmacology and resistance emergence not assessed.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://europepmc.org/article/MED/39319609

Needs source check · editorial details

The source has not been fully checked or contains conflicting information. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review scope and date are not recorded; source checked does not establish full-text review.

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.